Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor

Journal of Immunology

Volumn 156, Issue 7, 1996, Pages 2528-2533

  Brodbeck, William G ^a   Liu, Dacai ^a   Sperry, Jason ^a   Mold, Carolyn ^b   Medof, M Edward ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; DECAY ACCELERATING FACTOR;

ARTICLE; CELL SURFACE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME REGULATION; GENETIC TRANSFECTION; HEMOLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SHEEP ERYTHROCYTE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD55; CHO CELLS; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; CRICETINAE; HUMANS; MOLECULAR STRUCTURE; RECOMBINANT PROTEINS; SEQUENCE DELETION;

EID: 0029880767     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Nicholson-Weller, A., J. P. March, C. E. Rosen, D. B. Spicer, and K. F. Austen. 1985. Surface membrane expression by human blood leukocytes and platelets of decay accelerating factor, a regulatory protein of the complement system. Blood 65:1237.
2. Kinoshita, T., M. E. Medof, R. Silber, and V. Nussenzweig. 1985. Distribution of decay accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J. Exp. Med. 162:75.
3. Asch, A. S., T. Kinoshita, E. A. Jaffe, and V. Nussenzweig. 1986. Decay accelerating factor is present on cultured human umbilical vein endothelial cells. J. Exp. Med. 163:221.
4. Medof, M. E., E. I. Walter, J. L. Rutgers, D. M. Knowles, and V. Nussenzweig. 1987. Identification of the complement decay accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. 165:848.
5. Medof, M. E., T. Kinoshita, and V. Nussenzweig. 1984. Inhibition of complement activation on the surface of cells after incorporation of decay accelerating factor (DAF) into their membranes. J. Exp. Med. 160:1558.
6. Abbas, A. K., A. H. Lichtman, and J. S. Pober. 1994. The complement system. In Cellular and Molecular Immunology, Ch. 15. A. K. Abbas, A. H. Lichtman, and J. S. Pober, eds. W. B. Saunders Company, Philadelphia, pp. 293-316.
7. Yomtovian, R., G. M. Prince, and M. E. Medof. 1993. The molecular basis for paroxysmal nocturnal hemoglobinuria. Transfusion 33:852.
8. Medof, M. E., T. Kinoshita, R. Silber, and V. Nussenzweig. 1985. Amelioration of lyric abnormalities of paroxysmal nocturnal hemoglobinuria with decay accelerating factor. Proc. Natl. Acad. Sci. USA 82:2980.
9. Medof, M. E., D. M. Lublin, V. M. Holers, D. J. Ayers, R. R. Getty, J. F. Leykam, J. P. Atkinson, and M. L. Tykocinski. 1987. Cloning and characterization of cDNAs encoding the complete sequence of decay accelerating factor of human complement. Proc. Natl. Acad. Sci. USA 84:2007.
10. Caras, I. W., M. A. Davitz, L. Rhee, G. Weddell, D. W. Martin, Jr., and V. Nussenzweig. 1987. Cloning of decay accelerating factor suggests novel use of splicing to generate two proteins. Nature 325:545.
11. Reid, K. B. M., D. R. Bentley, R. D. Campbell, L. P. Chung, R. B. Sim, T. Christensen, and B. F. Tack. 1986. Complement system proteins which interact with C3b or C4b: a superfamily of structurally related proteins. Immunol. Today 7:230.
12. Walter, E. I., W. D. Ratnoff, K. E. Long, J. W. Kazura, and M. E. Medof. 1992. Effect of glycoinositolphospholipid anchor lipid groups on functional properties of decay accelerating factor protein in cells. J. Biol. Chem. 267:1245.
13. Medof, M. E., N. Shanmugam, and M. Tykocinski. 1996. Cell surface engineering with GPI-anchored proteins. Fed. Proc. In press.
14. Coyne, K. E., S. E. Hall, E. S. Thompson, M. A. Arce, T. Kinoshita, T. Fujita, D. J. Anstee, W. Rosse, and D. M. Lublin. 1992. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J. Immunol. 149:2906.
15. Ewulonu, U. K., R. Laksmeswari, and M. E. Medof. 1991. Characterization of the decay accelerating factor gene promoter region. Proc. Natl. Acad. Sci. USA 88: 4675.
16. Ausubel, F. M., R. Brent, R. E. Kington, D. A. Moore, J. Seidman, A. Smith, and K. Strohl. 1987. Current Protocols in Molecular Biology, Vol. 2. Greene Pub. Assoc. and Wiley Interscience, New York, pp. 1571-1576.
17. Post, T. W., M. A. Arce, M. K. Kiszewski, E. S. Thompson, J. P. Atkinson, and D. M. Lublin. 1990. Structure of the gene for human complement protein decay accelerating factor. J. Immunol. 144:740.
18. Cockett, M. I., C. R. Bebbington, and G. T. Yarronton. 1990. High level expression of tissue inhibitor of metalloproteinase in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology 8:662.
19. Davis, S. J., H. A. Ward, M. J. Puklavec, A. C. Willis, A. F. Williams, and A. N. Barclay. 1990. High level expression in Chinese hamster ovary cells of soluble forms of CD4 T lymphocyte glycoprotein including glycosylation variants. J. Biol. Chem. 265:10410.
20. Medof, M. E., E. I. Walter, W. L. Roberts, R. Haas, and T. L. Rosenberry. 1986. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry 25:6740.
21. Ratnoff, W. D., J. J. Knez, G. M. Prince, H. Okada, P. J. Lachmann, and M. E. Medof. 1992. Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. Clin. Exp. Immunol. 87:415.
22. Medof, M. E., E. I. Walter, W. I. Roberts, R. Haas, and T. L. Rosenberry. 1986. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry 25:6740.
23. Wang, R. H., G. Phillips, Jr., M. E. Medof, and C. Mold. 1993. Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J. Clin. Invest. 92:1326.
24. Seya, T., V. M. Holers, and J. P. Atkinson. 1985. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with C4b-binding protein (C4bp), and decay accelerating factor (DAF). J. Immunol. 135:2661.
25. Klickstein, L. B., T. J. Bartow, V. Meletic, L. D. Rabson, J. A. Smith, and D. T. Fearon. 1988. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1/CD35) by deletion mutagenesis. J. Exp. Med. 168:1699.
26. Krych, M., D. Hourcade, and J. P. Atkinson. 1991. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc. Natl. Acad. Sci. USA 88:4353.
27. 2 chimeric complement inhibitor. J. Exp. Med. 174:1451.
28. Reilly, B. D., S. C. Makrides, P. J. Ford, H. C. Marsh, Jr., and C. Mold. 1993. Identification of the C4b binding sites in CR1 using recombinant forms of CR1. J. Biol. Chem. 269:7696.
29. Krych, M., L. Clemenza, D. Howdeshell, R. Hauhart, D. Hourcade, and J. P. Atkinson. 1994. Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J. Biol. Chem. 269: 13273.
30. Pangburn, M. K. 1986. Differences between the binding sites of the complement regulatory proteins DAF, CR1 and factor H on C3 convertases. J. Immunol. 136:2216.
31. Fujita, T., T. Inoue, K. Ogawa, K. Iida, and N. Tamura. 1987. The mechanism of action of decay accelerating factor (DAF): DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J. Exp. Med. 166:1221.
32. Adams, E. M., N. C. Brown, M. Nunge, M. Krych, and J. P. Atkinson. 1991. Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J. Immunol. 147: 3005.